Anti mcd8 clone 2

GB1275 [previously known as ADH-503 (30 (link))] was used at a dose of 60 mg/kg in all tumor studies. A GB1275 stock was prepared in a vehicle solution of 0.5% Methylcellulose (Calbiochem) and 0.02% Tween-80 (Sigma) in water. Control animals were administered the vehicle alone. GB2175 or the vehicle was administered to animals twice daily by oral gavage (o.g.). For T cell depletion, CD4- and CD8-depleting antibodies (anti-mCD4 clone GK1.5 and anti-mCD8 clone 2.43, BioXCell) were administered via intraperitoneal (i.p.) injection every 3–4 days, with the first injection at 500 μg of antibody/animal before tumor implantation and subsequent injections at 250 μg of antibody/animal (39 (link)). CCR2i (PF-04136309, Pfizer) was used for the in vitro migration assay at 20 nM.

Immunotherapy IgGs were given intraperitoneally; anti-PD-1 (200 μg per dose, clone RMP1–14) was given every 3 days, whereas anti-CTLA4 (250 μg per dose, clone UC10-4F10-11) were given every 4 days. Anti-CTLA4 was discontinued after four doses, whereas anti-PD-1 was continued until day 30. All were purchased from BioXCell. For T cell depletion, CD4- and CD8-neutralizing IgG antibodies (anti-mCD4 clone GK1.5 and anti-mCD8 clone 2.43, BioXCell) were administered via intraperitoneal injection every 4 days, with the first injection containing 500 μg before tumor implantation and subsequent injections containing 250 μg.